Myriam Lereau Bernier, Dr.

Myriam.png Host Laboratory SAKAI LAB.
Position in LIMMS  Postdoctoral Researcher
Main Research Topic in LIMMS

Bio-MEMS-Development of a new microscale culture model to investigate the differentiation and maturation of induced pluripotent stem (iPS) cells to hepatocytes


iPS, hepatocytes, liver-on-chip, bioreactor

Contact LIMMS/CNRS-IIS (UMI 2820)
Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan
Phone:+81 (0)3 5452 6036 / Fax:+81 (0)3 5452 6088
E-mail myriam at


Short resume :
2016-now JSPS postdoctoral researcher (LIMMS, Tokyo)
2013-2014 CNRS IR (SysDiag – Bio-Rad/CNRS, Montpellier, France)
2011-2013 Postdoctoral researcher (Etablissement Français du Sang, Montpellier, France)
2006-2010 PhD student (INSERM – International Agency for Research on Cancer, Lyon, France)

↑Page top

Research Projects in Limms

Development of a new microscale culture model to investigate the differentiation and maturation of induced pluripotent stem cells to hepatocytes

Context: Hepatocytes differentiated from induced pluripotent stem (iPS) cells emerged as a promising source for in vitro liver model. iPS cells have two main properties: they may differentiate into all cell types that make up the body (pluripotency) and are able in ad hoc conditions to proliferate indefinitely in culture (self-renewal). Despite encouraging results, hepatocytes derived from iPS cells still present a differentiation pattern of primitiveness (AFP, SOX17) illustrating an incomplete maturation.


Objectives & Methods: The project liver-iPS on-chip aims to develop, from hepatocytes derived from iPS cells, a microfluidic liver tissue culture model, which will provide 3D, dynamics and mass transfer nutrient control in a micro-confined environment mimicking in vivo situations. This microfluidic bioreactor will then be used in epigenetic and hepatotoxicity studies.

↑Page top

Main publication List (papers, conferences and patent

    • Lereau M, Fournier-Wirth C, Mayen J, Farre C, Meyer A, Dugas V, Cantaloube JF, Chaix C, Vasseur JJ, Morvan F. Development of innovative and versatile polythiol probes for use on ELOSA or electrochemical biosensors: application in hepatitis C virus genotyping. Anal Chem 2013, 85(19):9204-12.

    • Lereau M, Gouas D, Villar S, Besaratinia A, Hautefeuille A, Berthillon P, Martel-Planche G, Nogueira da Costa A, Ortiz-Cuaran S, Hantz O, Pfeifer GP, Hainaut P, Chemin I. Interactions between hepatitis B virus and aflatoxin B(1): effects on p53 induction in HepaRG cells. J Gen Virol. 2012, 93:640-50.

    • Villar S, Le Roux-Goglin E, Gouas DA, Plymoth A, Ferro G, Boniol M, Lereau M, Bah E, Hall AJ, Wild CP, Mendy M, Norder H, van der Sande M, Whittle H, Friesen MD, Groopman JD, Hainaut P. Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection. Environ Health Perspect. 2011, 119(11):1635-40.

    • Galy O, Chemin I, Le Roux E, Villar S, Le Calvez-Kelm F, Lereau M, Gouas D, Vieco B, Suarez I, Navas MC, Chevallier M, Norder H, Srivatanakul P, Karalak A, Sangrajrang S, Trépo C, Hainaut P. Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand. Hepat Res Treat. 2011, 2011:697162.

    • 2 chapters in ”Hepatocellular Carcinoma: A Global Challenge” (2012, Nova Science Publishers):

    • Lereau M, Gouas D, Martel N, Dupinay T, Chemin I, “Challenges in Risk Assessment for Hepatocellular Carcinoma: Example of Hepatitis B Virus”

    • Gouas D, Lereau M, Ortiz-Cuaran S, Hainaut P, “Mutations of the Tumor Suppressor TP53 as Hallmarks of Distinct Pathway of Progression toward Hepatocellular Carcinoma”

  • Patents 

    • “Thiol compounds and the use thereof for the synthesis of modified oligonucleotides” (United States Patent Application 20150158964)

    • “Modified oligonucleotides comprising thiol functions and the use of same for the detection of nucleic acids”(Patent WO2013150122A1)

↑Page top